ArticleWideochirurgia i inne techniki maloinwazyjne = Videosurgery and other miniinvasive techniques2025
High conversion rate and survival benefits of transarterial chemoembolization with targeted immunotherapy in initially unresectable hepatocellular carcinoma: efficacy, safety, and optimal patient selection.
Article in Wideochirurgia i inne techniki maloinwazyjne = Videosurgery and other miniinvasive techniques, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionPrimary liver cancer ranks among the most prevalent malignancies globally. AIM We aimed to evaluate the efficacy and safety of transarterial chemoembolization (TACE) combined with targeted immunotherapy in initially unresectable hepatocellular carcinoma (uHCC), and identify patients most likely to benefit from this approach. MATERIALS AND
methodsWe retrospectively analyzed 68 uHCC patients treated with TACE with targeted immunotherapy at the Nanjing Drum Tower Hospital (April 2020-July 2024). Tumor response was assessed using the modified Response Evaluation Criteria in Solid Tumors. Progression‑free survival (PFS) and overall survival rates were estimated with the Kaplan-Meier analysis. Logistic and Cox regression models were used to identify the predictors of response and survival.
resultsThe objective response rate was 57.4%, and the disease control rate amounted to 89.7%. Median PFS was 13.8 months (95% CI, 8.7-19), with 6- and 12‑month PFS rates of 73.1% and 52.5%, respectively. Surgical conversion occurred in 52.9% of the patients, with 94.6% achieving R0 resection; 47.2% had ma‑ jor pathologic response. Multivariable analysis showed that fewer than 3 tumors (hazard ratio [HR], 6.35; P = 0.01) and absence of major vascular invasion (HR, 3.89; P = 0.03) independently predicted favorable response, while the male sex (HR, 0.27; P <0.001), China Liver Cancer (CNLC) stage Ib-IIa (HR, 6.05; P <0.001), and proton density fat fraction (PDFF) below 6.5% (P = 0.03) predicted longer PFS. Grade 3 adverse events occurred in 52.9% of the patients, with no grade 4-5 events. All were manageable.
conclusionsTACE with targeted immunotherapy yields high response and surgical conversion rates with acceptable toxicity in uHCC. Patients with CNLC stage Ib-IIa, fewer than 3 tumors, no major vascular inva‑ sion, and low PDFF derive the greatest benefit, supporting this approach as an effective conversion strategy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.